Myriad Genetics faces a sharp revenue decline and a failed Rule of 40 score, with late-cycle momentum risk and modest insider selling adding to the caution despite a strong earnings-surprise average.
Thesis pillars
- Rule Of Forty Failure→Stable
- Sharp Revenue Decline→Stable
- Late Cycle Momentum Risk↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Feb 24, 2026
Myriad Genetics, Inc. (MYGN) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $6.02: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality.
Myriad Genetics develops and commercializes molecular diagnostic tests spanning hereditary cancer risk (MyRisk), companion diagnostics (BRACAnalysis CDx, MyChoice CDx), prostate and breast cancer prognostics (Prolaris, EndoPredict), prenatal screening (Prequel, Foresight,... Read more
Sell if holding. Engine safety override at $6.02: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality. Chart setup: Death cross but MACD improving, RSI 78. Score 4.1/10, moderate confidence.
Passes 4/8 gates (positive momentum, clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Myriad Genetics, Inc.
About Myriad Genetics, Inc.
Myriad Genetics sells its MyRisk hereditary cancer test across eleven cancer types and BRACAnalysis CDx, the only FDA-approved germline BRCA companion diagnostic for breast cancer with additional approvals in ovarian, pancreatic and prostate cancer, alongside MyChoice CDx, an HRD companion diagnostic validated in more than 20,000 patients. The company invested $106.8 million in research and development during 2025, down from $113.4 million in 2024, as it advanced newer tests including Precise MRD for molecular residual disease monitoring and FirstGene, a combined prenatal screen in early-access clinical study. Myriad primarily sells through its own sales force in the United States and Japan, expanding into Europe and Asia-Pacific through indirect distribution channels.
Myriad organizes its testing menu around three franchises: Oncology, spanning hereditary cancer risk, companion diagnostics and molecular residual disease monitoring; Women's Health, covering prenatal screening and carrier testing; and Mental Health, anchored by the GeneSight pharmacogenomic test used to guide antidepressant and ADHD medication selection. The company competes against Natera, Foundation Medicine, Caris Life Sciences, Tempus, LabCorp, Quest Diagnostics, Veracyte, Guardant Health, MDxHealth and NeoGenomics across its oncology and diagnostics businesses, differentiating through its brand reputation in hereditary cancer testing and community-medicine commercial reach. In August 2024, Myriad divested its EndoPredict business to Eurobio Scientific while retaining rights to sell EndoPredict as a laboratory-developed test outside the European Union, and the company plans to discontinue U.S. EndoPredict sales during the first half of 2026 as it shifts focus toward the Cancer Care Continuum.
Show full overview
Myriad frames molecular residual disease testing, through its Precise MRD assay, as a significant new growth opportunity, but the test remains newly commercialized and competes in a market where Natera and Guardant Health already hold established MRD franchises with longer clinical track records. Because Myriad's community-medicine commercial reach is its stated competitive advantage for winning MRD share rather than a first-mover technology edge, the ultimate size of this opportunity depends on physician adoption patterns that the 10-K does not yet quantify with test-volume or revenue-contribution figures specific to Precise MRD.
See also: Healthcare · Diagnostics & Research
From Myriad Genetics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-27Recent Developments — Myriad Genetics, Inc.
Latest news
- NEWS Myriad Genetics Announces New Data from MONSTAR-SCREEN-3 Study — fiscal.ai Oct 22, 2026 positive
- NEWS 12 Health Care Stocks Moving In Tuesday's Intraday Session — benzinga Oct 20, 2026 neutral
- NEWS Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp — benzinga Oct 20, 2026 neutral
- NEWS Nasdaq Rises Over 100 Points; 3M Earnings Top Views — benzinga Oct 20, 2026 neutral
- NEWS Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday — benzinga Oct 20, 2026 positive
Generated 2026-10-27T12:14:06Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-06-23Item 5.02LOWOn June 17, 2026 director Daniel M. Skovronsky notified the Board of his resignation, effective immediately, not due to any disagreement with the company's operations, policies or practices. No successor named.SEC filing →
- 2026-06-04Item 5.02LOWAt Myriad Genetics' 2026 annual meeting, stockholders approved a 4,000,000-share increase to the Employee Stock Purchase Plan and a new 2026 Equity Incentive Plan reserving 8,463,567 shares. Routine equity-compensation plan approvals.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Revenue shrinking — -10.5% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -14.0%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.02: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality. Chart setup: Death cross but MACD improving, RSI 78. Prior stop was $5.60. Score 4.1/10, moderate confidence.
Analyst target $3.90 reached (−35.1% from $6.02); no take-profit level is published. Prior stop was $5.60. Stop-loss: $5.60.
Target reached (-35.1% upside); Quality below floor (3.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin 4.0%), Material insider selling (5 sells, 0.12% of cap).
Myriad Genetics, Inc. trades at a P/E of N/A (forward -10.2). TrendMatrix value score: 5.8/10. Verdict: Sell.
15 analysts cover MYGN with a consensus score of 2.5/5. Average price target: $4.
What does Myriad Genetics, Inc. do?Myriad Genetics develops and commercializes molecular diagnostic tests spanning hereditary cancer risk (MyRisk),...
Myriad Genetics develops and commercializes molecular diagnostic tests spanning hereditary cancer risk (MyRisk), companion diagnostics (BRACAnalysis CDx, MyChoice CDx), prostate and breast cancer prognostics (Prolaris, EndoPredict), prenatal screening (Prequel, Foresight, FirstGene, SneakPeek) and pharmacogenomic mental-health testing (GeneSight). The company sells these tests to providers and health systems primarily in the United States and Japan, competing against Natera, Foundation Medicine, Caris Life Sciences, Tempus, LabCorp and Quest Diagnostics. Myriad spent $106.8 million on research